Our Clinical Department has its own study center where the oncological studies are coordinated and supervised by a team. The study center serves as an interface between internal and external partners, especially when it comes to ensuring international ethical and scientific parameters and applicable legal requirements and guidelines.

Constantly striving to improve therapeutic options in the treatment of uro-oncological diseases is the prerequisite for excellent patient care. Clinical studies are an elementary component of this endeavor and an integral part of our medical and nursing activities. Since 2012, our Clinical Department has also had the authority to provide further training for the additional medical qualification "Drug-based tumor therapy", which can be acquired beyond the specialist examination.

As part of the treatment of advanced, i.e. metastatic, diseases, patients can be given new substances as part of national or international studies where possible. This is an attempt to positively influence the clinical prognosis compared to established treatment concepts.
At this point, we would like to inform oncologically affected patients as well as urologists and general practitioners in private practice about our current study protocols.
Inclusion of patients in a study protocol does not exempt them from routine visits to their urologist or family physician. Inclusion in the study takes place in consultation with the treating colleagues. By constantly exchanging information about the course of the disease and, if necessary, about undesirable side effects of the investigational drug, the practicing colleague is informed immediately.

Our primary goal is not only to improve the clinical prognosis of the individual patient and to stabilize any fracture-prone bone structures, but above all to improve quality of life through pain relief. In particular, the treatment of advanced clinical pictures is carried out in our Clinical Department as part of an interdisciplinary therapy decision if necessary, which takes radiotherapeutic treatment concepts into account, for example.

Prostate carcinoma

• PROCEED ( D0817R00074)
  Prospective, non-interventional study with the aim of demonstrating the clinical benefit of the combination olaparib+abiraterone under real-life conditions and to collect data for the use of the combination as 1L mCRPC therapy in NHA-pretreated patients.

none

Bladder carcinoma

• CA209-901
  Randomized phase III trial in previously untreated, metastatic or unresectable urothelial carcinoma.

• POTOMAC
  A randomized, unblinded, multicenter, global phase III study of durvalumab and Bacillus Calmette-Guérin (BCG) administered as combination therapy versus BCG alone in patients with high-risk non-muscle-invasive bladder cancer (POTOMAC).

• THOR
  Open-label phase III study with erdafitinib versus chemotherapy (vinflunine or docetaxel) in patients with unresectable urothelial carcinoma with FGFR mutation or translocation.

• VOLGA (D910C00001)
  Randomized, open-label, multicenter phase III study to determine the efficacy and safety of durvalumab + tremelimumab + enfortumab vedotin vs. durvalumab + enfortumab vedotin for the perioperative treatment of patients with muscle-invasive bladder cancer who are not suitable for cisplatin or do not wish to receive cisplatin.

Renal cell carcinoma

• CA209-914
  Phase III study in light cell, non-metastatic renal cell carcinoma with sarcomatoid components.

Prostate carcinoma

• Contact-02 (XL184-315)
  A randomized, open-label, controlled phase III study of cabozantinib (XL184) in combination with atezolizumab versus a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer.

G-NeSs
Partial kidney resection with recording of perioperative parameters and postoperative follow-up - a registry

PCO
Improving the quality of outcome in localized prostate cancer - international comparison of treatment and quality of outcome

Retrospective analysis of quality of life after renal tumor surgery
Quality of life and mental health in patients with organ-confined renal cell carcinoma after surgical treatment